optogenetics

Nanoscope’s MOGENRY BLA Accepted by FDA for Retinitis Pigmentosa

Dallas, Texas, USA, September 9, 2026 Nanoscope Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has...

By cGxPwire Editor
September 10, 2026

Bio-Pharma

Nanoscope Strengthens Global Regulatory Pathways for MCO-010 with FDA RMAT and Five EMA Orphan Designations

Nanoscope Therapeutics, a biotechnology company advancing disease-agnostic optogenetic therapies for retinal degenerations, announced a major global regulatory milestone with...

By cGxPwire Editor
September 2, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

optogenetics

Nanoscope’s MOGENRY BLA Accepted by FDA for Retinitis Pigmentosa

Nanoscope Strengthens Global Regulatory Pathways for MCO-010 with FDA RMAT and Five EMA Orphan Designations